PL1670433T3 - Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze - Google Patents
Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórzeInfo
- Publication number
- PL1670433T3 PL1670433T3 PL04790156T PL04790156T PL1670433T3 PL 1670433 T3 PL1670433 T3 PL 1670433T3 PL 04790156 T PL04790156 T PL 04790156T PL 04790156 T PL04790156 T PL 04790156T PL 1670433 T3 PL1670433 T3 PL 1670433T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical formulation
- transdermal pharmaceutical
- minimizing skin
- skin residues
- active agent
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 150000001346 alkyl aryl ethers Chemical class 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51061303P | 2003-10-10 | 2003-10-10 | |
| PCT/EP2004/011175 WO2005039531A1 (en) | 2003-10-10 | 2004-10-06 | Transdermal pharmaceutical formulation for minimizing skin residues |
| EP04790156A EP1670433B1 (en) | 2003-10-10 | 2004-10-06 | Transdermal pharmaceutical formulation for minimizing skin residues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1670433T3 true PL1670433T3 (pl) | 2013-03-29 |
Family
ID=34520020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04790156T PL1670433T3 (pl) | 2003-10-10 | 2004-10-06 | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US7335379B2 (pl) |
| EP (1) | EP1670433B1 (pl) |
| JP (1) | JP5619337B2 (pl) |
| AT (1) | ATE534373T1 (pl) |
| AU (1) | AU2004283431B2 (pl) |
| BR (1) | BRPI0414551B8 (pl) |
| CA (1) | CA2538856C (pl) |
| DK (1) | DK1670433T3 (pl) |
| ES (1) | ES2377932T3 (pl) |
| MX (2) | MXPA06003316A (pl) |
| NZ (1) | NZ546106A (pl) |
| PL (1) | PL1670433T3 (pl) |
| PT (1) | PT1670433E (pl) |
| WO (1) | WO2005039531A1 (pl) |
| ZA (1) | ZA200602046B (pl) |
Families Citing this family (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| AU8206401A (en) | 2000-08-03 | 2002-02-18 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| KR20050045946A (ko) | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
| EP2907503A1 (en) | 2003-04-10 | 2015-08-19 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
| US8883769B2 (en) * | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
| US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| US7387788B1 (en) * | 2003-10-10 | 2008-06-17 | Antares Pharma Ipl Ag | Pharmaceutical compositions of nicotine and methods of use thereof |
| PL1670433T3 (pl) | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
| ES2265239B1 (es) * | 2004-09-23 | 2008-02-01 | Laboratorio Reig Jofre, S.A. | Composicion farmaceutica para administracion transdermica. |
| JP2008530139A (ja) * | 2005-02-14 | 2008-08-07 | ニューロジェシックス， インコーポレイテッド | Ｔｒｐｖ１アゴニストを送達するための装置 |
| DE102005015128B4 (de) * | 2005-03-31 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Wafer enthaltend Steroidhormone |
| US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| KR20130114229A (ko) * | 2005-06-03 | 2013-10-16 | 애크럭스 디디에스 피티와이 리미티드 | 경피 약물 전달 방법 및 조성물 |
| CA2610708C (en) * | 2005-06-03 | 2013-10-08 | Acrux Dds Pty Ltd | Method and composition for transdermal drug delivery |
| AU2006254742C1 (en) * | 2005-06-03 | 2011-11-03 | Acrux Dds Pty Ltd | Method and composition for transdermal drug delivery |
| WO2006138715A1 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company, Inc. | Estrogen compositions for vaginal administration |
| US10016442B2 (en) | 2005-06-16 | 2018-07-10 | Allergan Pharmaceuticals International Limited | Estrogen compositions for vaginal administration |
| EP1898880A2 (en) * | 2005-06-16 | 2008-03-19 | Warner Chilcott Company Inc. | Gel compositions for topical administration |
| GB0517840D0 (en) * | 2005-09-02 | 2005-10-12 | Henderson Morley Plc | Topical anti viral formulations |
| CA2646667C (en) | 2006-04-21 | 2014-03-11 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
| FR2900575B1 (fr) * | 2006-05-05 | 2008-10-17 | Anteis Sa | Gel biocompatible a liberation controlee, son procede de preparation et son utilisation |
| US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| US9248104B2 (en) * | 2006-08-17 | 2016-02-02 | Core Tech Solutions, Inc. | Transdermal methods and systems for treating Alzheimer's disease |
| TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| RU2009117468A (ru) * | 2006-10-12 | 2010-11-20 | Рото Фармасьютикал Ко., Лтд. (Jp) | Наружный препарат для кожи |
| DE102006056783A1 (de) * | 2006-12-01 | 2008-06-05 | Lts Lohmann Therapie-Systeme Ag | Zubereitung zur transdermalen Verabreichung von Galanthamin |
| KR101408488B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법 |
| CN101588802A (zh) * | 2006-12-01 | 2009-11-25 | 日东电工株式会社 | 含有稳定化的多奈哌齐的贴剂 |
| WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
| MX2009007366A (es) | 2007-01-11 | 2009-07-16 | Acrux Dds Pty Ltd | Implemento para untar. |
| CA2675797A1 (en) * | 2007-01-16 | 2008-07-24 | Dermworx, Incorporated | Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
| US9283177B2 (en) * | 2007-01-16 | 2016-03-15 | Juventio, Llc | Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
| WO2008128280A1 (en) * | 2007-04-20 | 2008-10-30 | Acrux Dds Pty Ltd | Method and system for transdermal administration of volatile active |
| AR068409A1 (es) * | 2007-09-14 | 2009-11-18 | Drugtech Corp | Composiciones farmaceuticas, transdermicas sin alcohol |
| AR068408A1 (es) * | 2007-09-14 | 2009-11-18 | Drugtech Corp | Pulverizacion de hormonas transdermicas |
| KR101583680B1 (ko) * | 2007-10-15 | 2016-01-08 | 알자 코퍼레이션 | 펜타닐의 1일-1회 교체 경피 투여 |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| US8927537B2 (en) * | 2007-12-21 | 2015-01-06 | Nuvo Research Inc. | Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs |
| CA2724502A1 (en) * | 2008-05-30 | 2009-12-03 | Nitto Denko Corporation | Adhesive preparation containing donepezil, and package of the same |
| BRPI0912099A2 (pt) * | 2008-05-30 | 2015-10-06 | Eisai R&D Man Co Ltd | preparação percutaneamente absorvível |
| ES2639576T3 (es) | 2008-06-19 | 2017-10-27 | Lts Lohmann Therapie-Systeme Ag | Composición para administración transdérmica de agentes activos catiónicos |
| EP2363116A1 (en) * | 2008-06-25 | 2011-09-07 | US Worldmeds LLC | Sustained-release formulations comprising lofexidine for oral delivery |
| WO2010008600A1 (en) * | 2008-07-16 | 2010-01-21 | Dermworx Incorporated | Topical drug delivery system |
| EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
| CA2738524C (en) * | 2008-10-02 | 2013-11-26 | Mylan Inc. | Method for making a multilayer adhesive laminate |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| HUP0900073A2 (en) * | 2009-02-06 | 2010-11-29 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Process and equipment for inquiry medical product on dermal surface |
| CN101940790B (zh) * | 2009-07-01 | 2012-07-25 | 润和生物医药科技(汕头)有限公司 | 一种新型促渗剂组合物及其在透皮给药系统中的应用 |
| JP5675225B2 (ja) * | 2009-09-01 | 2015-02-25 | 久光製薬株式会社 | 貼付製剤 |
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| AU2011248904B2 (en) | 2010-04-30 | 2014-02-27 | Teikoku Seiyaku Co., Ltd. | Propynylaminoindan transdermal compositions |
| GB2482868A (en) * | 2010-08-16 | 2012-02-22 | Franciscus Wilhelmus Henricus Maria Merkus | A testosterone liquid spray formulation for oromucosal administration |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| AU2011329782A1 (en) | 2010-11-18 | 2013-06-20 | White Mountain Pharma, Inc. | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
| BR112013012799A8 (pt) * | 2010-12-02 | 2018-01-09 | Nexmed Holdings Inc | formulário de dosagem, método de facilitação do transporte de um composto farmaceuticamente ativo através de uma membrana biológica ou tecido e composto farmaceuticamente ativo |
| JO3755B1 (ar) * | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| AU2012214085B2 (en) | 2011-02-11 | 2015-07-09 | Nicoventures Trading Limited | Inhaler component |
| KR101853082B1 (ko) | 2011-03-24 | 2018-04-27 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 활성제층 및 활성제 변환층을 포함하는 경피 조성물 |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| AR086400A1 (es) | 2011-05-13 | 2013-12-11 | Trimel Pharmaceuticals Corp | Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo |
| CA3034552C (en) * | 2011-05-15 | 2023-02-07 | Acerus Biopharma Inc. | Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration |
| EP3311802B1 (en) * | 2011-05-25 | 2023-11-01 | Dermaliq Therapeutics, Inc. | Topical pharmaceutical composition based on semifluorinated alkanes |
| CA2839624A1 (en) * | 2011-06-27 | 2013-01-03 | Ferring B.V. | Applicator system for applying a viscous liquid to the human skin |
| JP2013060393A (ja) * | 2011-09-13 | 2013-04-04 | Nitto Denko Corp | 経皮吸収促進用組成物および貼付製剤 |
| JP5820206B2 (ja) | 2011-09-13 | 2015-11-24 | 日東電工株式会社 | 経皮吸収促進用組成物および貼付製剤 |
| JP5820207B2 (ja) | 2011-09-13 | 2015-11-24 | 日東電工株式会社 | 経皮吸収促進用組成物および貼付製剤 |
| WO2013070526A1 (en) | 2011-11-09 | 2013-05-16 | Teikoku Pharma Usa, Inc. | Methods for the treatment of skin neoplasms |
| CN103181894B (zh) * | 2011-12-30 | 2015-07-15 | 北大方正集团有限公司 | 萘丁美酮喷雾剂及其制备方法 |
| KR101976137B1 (ko) | 2012-01-25 | 2019-05-09 | 한미약품 주식회사 | 두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법 |
| RU2014152445A (ru) | 2012-07-12 | 2016-08-27 | Ферринг Б.В. | Композиции на основе диклофенака |
| JP6226278B2 (ja) * | 2012-08-03 | 2017-11-08 | 国立大学法人愛媛大学 | 免疫細胞の活性化抑制剤およびその用途 |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| EP4342537A3 (en) | 2012-09-12 | 2024-07-03 | Novaliq GmbH | Semifluorinated alkane compositions |
| EP3100722B1 (en) | 2012-09-12 | 2024-03-20 | Novaliq GmbH | Semifluorinated alkanes for use in solubilizing meibum |
| US8822537B2 (en) * | 2012-09-27 | 2014-09-02 | Achelios Therapeutics, Inc. | Topical ketoprofen composition |
| CN104797245B (zh) | 2012-11-02 | 2018-05-04 | 帝国制药美国公司 | 丙炔基氨基茚满透皮组合物 |
| WO2014076569A2 (en) * | 2012-11-14 | 2014-05-22 | Trimel Biopharma Srl | Controlled release topical testosterone formulations and methods |
| WO2014111790A2 (en) | 2013-01-15 | 2014-07-24 | Zydus Technologies Limited | Stable transdermal pharmaceutical drug delivery system comprising rivastigmine |
| US9433680B2 (en) | 2013-01-31 | 2016-09-06 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9452173B2 (en) | 2013-01-31 | 2016-09-27 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US9446131B2 (en) | 2013-01-31 | 2016-09-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| USD750788S1 (en) | 2013-11-26 | 2016-03-01 | Acrux Dds Pty Ltd | Topical spreading applicator |
| USD749225S1 (en) | 2013-11-26 | 2016-02-09 | Acrux Dds Pty Ltd | Topical spreading applicator |
| SI3119410T1 (sl) * | 2014-03-18 | 2022-10-28 | Institut de Recherche en Semiochimie et Ethologie Appliquee | Feromon za pomirjanje mačk |
| CN106413695B (zh) | 2014-04-08 | 2019-12-10 | 帝国制药美国公司 | 利伐斯的明透皮组合物及其使用方法 |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| KR20170117390A (ko) | 2014-12-23 | 2017-10-23 | 스티븐 호프만 | 경피 제형물 |
| US9687528B2 (en) * | 2014-12-23 | 2017-06-27 | Steven Hoffman | Transdermal formulations |
| US10149828B2 (en) | 2015-01-09 | 2018-12-11 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
| US20180133239A1 (en) * | 2015-06-08 | 2018-05-17 | Dermarc LLC | Therapeutic composition |
| WO2016200672A1 (en) * | 2015-06-08 | 2016-12-15 | Cutanea Life Sciences, Inc. | Therapeutic composition |
| EP3356313B1 (en) | 2015-09-30 | 2020-05-06 | Novaliq GmbH | 2-perfluorohexyl octane for ophthalmic administration |
| RU2699674C1 (ru) * | 2015-09-30 | 2019-09-09 | Фуджифилм Корпорэйшн | Композиция для чрескожной абсорбции |
| DE202016008738U1 (de) | 2015-09-30 | 2019-04-09 | Novaliq Gmbh | Semifluorierte Verbindungen und ihre Zusammensetzungen |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| US9901576B2 (en) | 2015-11-20 | 2018-02-27 | West-Ward Pharmaceuticals International Limited | Stable formulation of phenobarbital sodium injection |
| CN108697655B (zh) | 2015-12-30 | 2021-12-10 | 考里安公司 | 用于长期透皮施药的系统和方法 |
| US11865113B2 (en) * | 2016-06-06 | 2024-01-09 | Lipidio Pharmaceuticals Inc. | Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH) |
| WO2017218783A1 (en) * | 2016-06-17 | 2017-12-21 | Benchmark Cosmetic Laboratories, Inc. | Sphere forming compositions |
| EP3474831A1 (en) | 2016-06-23 | 2019-05-01 | Corium International, Inc. | Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent |
| JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
| JP7469879B2 (ja) | 2016-07-27 | 2024-04-17 | コリウム， エルエルシー | 経口送達と生物学的に同等である薬物動態を有する経皮送達システム |
| SG11201900692WA (en) | 2016-07-27 | 2019-02-27 | Corium Int Inc | Donepezil transdermal delivery system |
| AU2017301929B2 (en) | 2016-07-27 | 2023-03-02 | Corium Pharma Solutions, Inc. | Memantine transdermal delivery systems |
| PL3515420T3 (pl) | 2016-09-22 | 2024-04-08 | Novaliq Gmbh | Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek |
| CA3036306C (en) | 2016-09-23 | 2024-05-14 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| EP3399962B1 (en) | 2016-12-23 | 2020-06-10 | Novaliq GmbH | Ophthalmic composition for treatment of dry eye disease |
| CA3058097C (en) | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| EA201992532A1 (ru) | 2017-04-24 | 2020-04-03 | Чейс Терапьютикс Корпорейшн | Композиции и способ для лечения депрессии |
| GB2562270B (en) | 2017-05-10 | 2020-07-01 | Hyphens Pharma Pte Ltd | Skin barrier composition |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| CN110869020B (zh) * | 2017-07-11 | 2023-02-03 | 希尔帕医疗保健有限公司 | 度他雄胺的局部用组合物 |
| EP3677253A4 (en) | 2017-09-01 | 2020-11-04 | JW Pharmaceutical Corporation | SOLID PREPARATION INCLUDING DUTASTERIDE AND RELATED PREPARATION PROCESS |
| US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| MX2020003534A (es) | 2017-09-27 | 2020-07-29 | Novaliq Gmbh | Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares. |
| CN119909046A (zh) | 2017-10-04 | 2025-05-02 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| WO2019126531A1 (en) | 2017-12-20 | 2019-06-27 | Corium, Inc. | Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point |
| WO2019140087A1 (en) | 2018-01-10 | 2019-07-18 | Celista Pharmaceuticals Llc | Testosterone transdermal spray with film |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| CN112153970A (zh) | 2018-04-27 | 2020-12-29 | 诺瓦利克有限责任公司 | 用于治疗青光眼的包含他氟前列素的眼用组合物 |
| CN119097625A (zh) | 2018-06-04 | 2024-12-10 | 阿尔库缇斯生物疗法股份有限公司 | 改善罗氟司特皮肤渗透滞后时间的方法和制剂 |
| CA3105187A1 (en) | 2018-06-28 | 2020-01-02 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
| US12186326B2 (en) | 2018-07-05 | 2025-01-07 | Celista Pharmaceuticals Llc | Testosterone and estradiol transdermal spray |
| US12029757B2 (en) | 2018-09-27 | 2024-07-09 | Dermaliq Therapeutics, Inc. | Lipid barrier repair |
| CA3111870C (en) | 2018-09-27 | 2022-04-12 | Novaliq Gmbh | Topical sunscreen formulation |
| CN112823020A (zh) | 2018-10-12 | 2021-05-18 | 诺瓦利克有限责任公司 | 用于治疗干眼病的眼用组合物 |
| US11311529B2 (en) * | 2018-11-08 | 2022-04-26 | Varsona Therapeutics, Inc. | Topical formulations of 5-α-reductase inhibitors and uses thereof |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| WO2021054257A1 (ja) * | 2019-09-18 | 2021-03-25 | 久光製薬株式会社 | ロピニロール含有貼付剤及びロピニロールの皮膚透過性向上方法 |
| RU2736081C1 (ru) * | 2019-12-02 | 2020-11-11 | федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Пластырь трансдермальный с гликлазидом |
| WO2021113411A1 (en) * | 2019-12-02 | 2021-06-10 | Ampersand Biopharmaceuticals, Inc. | Transdermal penetrant formulations for vitamins, minerals and supplements |
| JP2023511250A (ja) * | 2020-01-13 | 2023-03-17 | スタートン セラピューティクス インコーポレイテッド | 最小用量のオランザピンによる嘔吐及び悪心の治療 |
| KR102352888B1 (ko) | 2020-01-15 | 2022-01-18 | 한국프라임제약주식회사 | 두타스테리드를 포함하는 경구용 약제학적 조성물 |
| CA3169241A1 (en) | 2020-02-27 | 2021-09-02 | Dario N.R. CARRARA | Topical diclofenac compositions and methods |
| WO2021189077A1 (en) * | 2020-03-18 | 2021-09-23 | Chemistryrx | Methods for treating acne |
| US20220133658A1 (en) * | 2020-09-11 | 2022-05-05 | Ps Therapy, Inc. | Topical analgesic compositions and methods of use |
| WO2022055927A1 (en) * | 2020-09-11 | 2022-03-17 | Ps Therapy Ltd. | Topical compositions and methods of use |
| CA3198952A1 (en) * | 2020-11-23 | 2022-05-27 | Dermavant Sciences GmbH | Gel, ointment, and foam formulations of tapinarof and methods of use |
| ES3033851T3 (en) | 2020-12-04 | 2025-08-08 | Arcutis Biotherapeutics Inc | Topical roflumilast formulation having antifungal properties |
| CA3242322A1 (en) | 2021-12-28 | 2023-07-06 | Arcutis Biotherapeutics, Inc. | Topical roflumilast aerosol foams |
| US12060328B2 (en) | 2022-03-04 | 2024-08-13 | Reset Pharmaceuticals, Inc. | Co-crystals or salts of psilocybin and methods of treatment therewith |
| CN115414320A (zh) * | 2022-09-14 | 2022-12-02 | 四川农业大学 | 一种具有抗真菌作用的1,8-桉叶油素纳米乳凝胶剂 |
| KR20250057103A (ko) | 2022-09-15 | 2025-04-28 | 아큐티스 바이오테라퓨틱스, 인크. | 로플루밀라스트 및 많은 양의 약물을 용해시킬 수 있는 용매의 약학 조성물 |
| US20240148640A1 (en) * | 2022-11-04 | 2024-05-09 | Celista Pharmaceuticals Llc | Topical oxybutynin for hot flashes |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
Family Cites Families (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1979385A (en) * | 1931-11-10 | 1934-11-06 | Carbide & Carbon Chem Corp | Cosmetic preparation |
| US2990332A (en) * | 1958-04-02 | 1961-06-27 | Wallace & Tiernan Inc | Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith |
| US3143465A (en) * | 1961-06-19 | 1964-08-04 | Wallace & Tiernan Inc | Pharmaceutical preparations comprising phosphorus containing cation exchange resins having a basic drug adsorbed thereon; and treatment therewith |
| US3650280A (en) * | 1969-12-03 | 1972-03-21 | David Roberts | Cosmetic treatment of hair with thiourea or urea and glyoxal |
| US5736577A (en) * | 1995-01-31 | 1998-04-07 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin |
| DE2350315C2 (de) * | 1973-10-06 | 1984-01-12 | Johnson & Johnson GmbH, 4000 Düsseldorf | Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung |
| US3891696A (en) * | 1973-11-02 | 1975-06-24 | Interx Research Corp | Novel, transient pro-drug forms of l-dopa |
| US4316893A (en) * | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4082881A (en) * | 1976-12-23 | 1978-04-04 | E. R. Squibb & Sons, Inc. | Topical and other type pharmaceutical formulations containing isosorbide carrier |
| US4221778A (en) | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
| US4315925A (en) * | 1980-05-30 | 1982-02-16 | University Of Kentucky Research Foundation | Method of administering natural female sex hormones |
| US4383993A (en) * | 1980-05-30 | 1983-05-17 | University Of Kentucky Research Foundation | Nasal dosage forms containing natural female sex hormones |
| FR2518879A1 (fr) | 1981-12-30 | 1983-07-01 | Besins Jean | Medicament a base d'oestradiol pour le traitement de la pathologie menopausique |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| DE3333240A1 (de) | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
| CA1249968A (en) * | 1984-04-05 | 1989-02-14 | Kazuo Kigasawa | Ointment base |
| US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
| US4597961A (en) * | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US5783207A (en) * | 1985-05-01 | 1998-07-21 | University Of Utah Research Foundation | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine |
| DE3522550A1 (de) | 1985-06-24 | 1987-01-02 | Klinge Co Chem Pharm Fab | Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung |
| US5731303A (en) * | 1985-12-04 | 1998-03-24 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery compositions |
| US4764381A (en) * | 1985-12-06 | 1988-08-16 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
| US4801586A (en) | 1986-04-23 | 1989-01-31 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agents |
| CA1272922A (en) | 1986-06-03 | 1990-08-21 | Peter William Berry | Drug delivery device, its preparation and use |
| ES2042564T3 (es) | 1986-06-13 | 1993-12-16 | Procter & Gamble | Composiciones por via topica penetrantes mejoradas para aumentar el crecimiento del cabello. |
| US5041439A (en) * | 1986-06-13 | 1991-08-20 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| US4908389A (en) | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
| MY102980A (en) | 1986-10-31 | 1993-03-31 | Pfizer | Transdermal flux enhancing compositions |
| US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| EP0267617B1 (en) | 1986-11-14 | 1992-06-24 | Theratech, Inc. | Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols |
| US4788062A (en) | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
| US4832953A (en) | 1987-08-13 | 1989-05-23 | Alza Corporation | Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix |
| US5925372A (en) * | 1987-12-16 | 1999-07-20 | Novartis Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
| US5064654A (en) | 1989-01-11 | 1991-11-12 | Ciba-Geigy Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
| US5225189A (en) * | 1988-02-18 | 1993-07-06 | The Upjohn Company | Minoxidil gel |
| US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US5004610A (en) * | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
| US4942158A (en) | 1988-10-13 | 1990-07-17 | Eastman Kodak | Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol |
| US4883660A (en) | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
| ES2060148T3 (es) | 1989-02-28 | 1994-11-16 | Teijin Ltd | Cataplasma y su preparacion. |
| US5059426A (en) * | 1989-03-22 | 1991-10-22 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
| US4973468A (en) * | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
| US5053227A (en) * | 1989-03-22 | 1991-10-01 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
| US4956171A (en) | 1989-07-21 | 1990-09-11 | Paco Pharmaceutical Services, Inc. | Transdermal drug delivery using a dual permeation enhancer and method of performing the same |
| US5232703A (en) * | 1989-07-21 | 1993-08-03 | Izhak Blank | Estradiol compositions and methods for topical application |
| DE69007886T2 (de) * | 1989-07-21 | 1994-11-17 | Izhak Blank | Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung. |
| US5112614A (en) | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
| US5230896A (en) * | 1989-10-12 | 1993-07-27 | Warner-Lambert Company | Transdermal nicotine delivery system |
| DE3937271A1 (de) * | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
| US5188825A (en) * | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
| JP3273430B2 (ja) | 1989-12-28 | 2002-04-08 | 日東電工株式会社 | エストロゲン含有ゲル製剤 |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5371005A (en) | 1990-04-10 | 1994-12-06 | Kyowa Hakko Kogyo Co., Ltd. | Cholesterol oxidase |
| US5602017A (en) | 1990-04-10 | 1997-02-11 | Kyowa Hakko Kogyo Co., Ltd. | Cholesterol oxidase |
| US5149719A (en) | 1990-04-27 | 1992-09-22 | Minnesota Mining And Manufacturing Company | Composition for transdermal penetration of medicaments |
| US5397771A (en) | 1990-05-10 | 1995-03-14 | Bechgaard International Research And Development A/S | Pharmaceutical preparation |
| ATE135227T1 (de) | 1990-07-20 | 1996-03-15 | Slagel David | Produkte und verfahren zur behandlung des verdauungskanals |
| JP2883700B2 (ja) | 1990-08-24 | 1999-04-19 | 花王株式会社 | 毛髪化粧料 |
| GB9021674D0 (en) * | 1990-10-05 | 1990-11-21 | Ethical Pharma Ltd | Transdermal device |
| FR2668945B1 (fr) | 1990-11-12 | 1993-02-19 | Theramex | Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus. |
| US5164190A (en) | 1990-12-11 | 1992-11-17 | Theratech, Inc. | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
| US5175190A (en) | 1991-02-15 | 1992-12-29 | The University Of British Columbia | Medium chain fatty acids of C8-10 for the treatment of skin lesions |
| US5238933A (en) * | 1991-10-28 | 1993-08-24 | Sri International | Skin permeation enhancer compositions |
| DE4210711A1 (de) | 1991-10-31 | 1993-05-06 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | Transdermale therapeutische systeme mit kristallisationsinhibitoren |
| US5786357A (en) * | 1991-12-02 | 1998-07-28 | Sepracor Inc. | Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone |
| US5178879A (en) * | 1992-04-17 | 1993-01-12 | Michael Adekunle | Capsaicin gel |
| US5453279A (en) | 1992-04-21 | 1995-09-26 | Tbs Laboratories, Inc. | Enhancing transdermal absorption compositions; transdermal dosage form; and process |
| US5900250A (en) * | 1992-05-13 | 1999-05-04 | Alza Corporation | Monoglyceride/lactate ester permeation enhancer for oxybutnin |
| US5278176A (en) * | 1992-08-21 | 1994-01-11 | Abbott Laboratories | Nicotine derivatives that enhance cognitive function |
| US5458884A (en) | 1992-09-10 | 1995-10-17 | Britton; Peter | Bioerodible device for administering active ingredients |
| FR2695826B1 (fr) | 1992-09-21 | 1995-01-06 | Theramex | Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention. |
| JP2937667B2 (ja) * | 1992-11-19 | 1999-08-23 | 高砂香料工業株式会社 | 尋常性ざ瘡用皮膚外用剤 |
| WO1994012146A1 (en) | 1992-11-23 | 1994-06-09 | Estee Lauder, Inc. | Self-tanning cosmetic compositions and methods of using the same |
| US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| DE4311252A1 (de) * | 1993-04-06 | 1994-10-13 | Boehringer Mannheim Gmbh | Bestimmung eines Analyten in einer Probeflüssigkeit |
| US5576279A (en) | 1993-05-17 | 1996-11-19 | Helene Curtis, Inc. | Stable conditioning shampoo containing an anionic surfactant a fatty alcohol, and polyethyleneimine |
| US5503844A (en) | 1993-05-18 | 1996-04-02 | Mli Acquisition Corp. Ii | Foam laminate transdermal patch |
| GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| CA2166869A1 (en) * | 1993-07-09 | 1995-01-19 | Ooi Wong | Method and device for providing nicotine replacement therapy transdermally/transbuccally |
| JP3223404B2 (ja) | 1993-10-30 | 2001-10-29 | 日本ソシア株式会社 | 育毛・養毛剤 |
| US5549888A (en) * | 1994-01-31 | 1996-08-27 | Procter & Gamble | Aqueous topical anti-acne compositions of low pH |
| CN1106259A (zh) | 1994-02-05 | 1995-08-09 | 日东制药株式会社 | 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂 |
| DE4405898A1 (de) * | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
| US5503843A (en) | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
| AU2345695A (en) * | 1994-04-28 | 1995-11-29 | F. Hoffmann-La Roche Ag | Pharmaceutical composition for transdermal delivery |
| US5580574A (en) * | 1994-04-28 | 1996-12-03 | Hoffmann-La Roche Inc. | Pharmaceutical composition for transdermal delivery |
| US5552153A (en) | 1994-04-28 | 1996-09-03 | Hoffman-La Roche Inc. | Pharmaceutical composition for transdermal delivery |
| US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| FR2722102B1 (fr) * | 1994-07-11 | 1996-08-23 | Cird Galderma | Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses |
| US6309843B1 (en) | 1994-10-25 | 2001-10-30 | The Curators Of The University Of Missouri | Glycoprotein for use in determining endometrial receptivity |
| US5831035A (en) | 1994-10-25 | 1998-11-03 | Curators Of The University Of Missouri | Antibody against human endometrial stromal cell glycoprotein |
| US5686100A (en) | 1994-11-22 | 1997-11-11 | E.R. Squibb & Sons, Inc. | Prophylactic and therapeutic treatment of skin sensitization and irritation |
| US5532278A (en) * | 1995-01-31 | 1996-07-02 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin |
| US5629021A (en) * | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
| US5677346A (en) | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| AT408067B (de) | 1995-03-17 | 2001-08-27 | Gebro Pharma Gmbh | Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung |
| US5601839A (en) | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
| US6124355A (en) | 1995-05-22 | 2000-09-26 | Guittard; George V. | Oxybutynin therapy |
| US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
| ES2098193B1 (es) | 1995-07-21 | 1997-12-01 | Gomez Jesus Calderon | Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea. |
| US5922349A (en) * | 1995-09-28 | 1999-07-13 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| FR2739558B1 (fr) * | 1995-10-05 | 1997-11-28 | Innothera Lab Sa | Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale |
| JP4036496B2 (ja) | 1995-10-24 | 2008-01-23 | リンテック株式会社 | ゲル製剤の製造方法 |
| US5817527A (en) | 1995-11-06 | 1998-10-06 | Chiron Diagnostics Corporation | Conjugation of ligand to immobilized protein in organic solvent |
| DE19548332A1 (de) | 1995-12-22 | 1997-07-10 | Rotta Res Bv | Hormonpflaster |
| EP0785211A1 (en) | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New substituted 19-nor-pregnane derivatives |
| EP0785212A1 (en) | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New 19-nor-pregnene derivatives |
| US5889028A (en) * | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| US6923983B2 (en) * | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
| AU2036297A (en) | 1996-03-20 | 1997-10-10 | Glaxo Group Limited | Topical formulations of aciclovir |
| GB9607955D0 (en) | 1996-04-17 | 1996-06-19 | Tillotts Pharma Ag | Hydrophobic carbomer salt compositions |
| US5814659A (en) | 1996-04-23 | 1998-09-29 | Dtr Dermal Therapy (Barbados) Inc. | Topical analgesic composition |
| DE19619045C1 (de) * | 1996-05-02 | 1997-11-13 | Jenapharm Gmbh | Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen |
| GB9610862D0 (en) * | 1996-05-23 | 1996-07-31 | Evans Brian K | Pharmaceutical products |
| IT1283102B1 (it) | 1996-06-06 | 1998-04-07 | Permatec Nv | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele |
| GB9614902D0 (en) * | 1996-07-16 | 1996-09-04 | Rhodes John | Sustained release composition |
| US6123961A (en) | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
| US5760096A (en) | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
| US5855920A (en) * | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
| US5945405A (en) * | 1997-01-17 | 1999-08-31 | Abbott Laboratories | Crystal form O of clarithromycin |
| US20010023261A1 (en) | 1997-01-27 | 2001-09-20 | Lg Chemical Limited. | Novel composition for the transdermal administration of drugs |
| IT1289973B1 (it) | 1997-02-25 | 1998-10-19 | Helsinn Healthcare Sa | Sistemi gelificati di nimesulide per uso topico |
| US6093722A (en) * | 1997-02-26 | 2000-07-25 | Sankyo Company, Limited | Method for treating prostate cancer |
| US6008192A (en) | 1997-03-12 | 1999-12-28 | Abbott Laboratories | Hydrophilic binary systems for the administration of lipophilic compounds |
| US6426078B1 (en) | 1997-03-17 | 2002-07-30 | Roche Vitamins Inc. | Oil in water microemulsion |
| PT986403E (pt) | 1997-06-13 | 2004-04-30 | Cydex Inc | Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua |
| US6034079A (en) | 1997-08-11 | 2000-03-07 | University Of South Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| GB9720470D0 (en) | 1997-09-25 | 1997-11-26 | Ethical Pharmaceuticals South | Inhibition of crystallization in transdermal devices |
| US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| US5968919A (en) | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
| BR9814014B1 (pt) | 1997-11-10 | 2014-10-07 | Strakan Int Ltd | Composição para aplicação tópica tendo propriedades de melhora da penetração |
| FR2776191B1 (fr) | 1998-03-23 | 2002-05-31 | Theramex | Composition hormonale topique a effet systemique |
| US20010038855A1 (en) | 1998-06-05 | 2001-11-08 | Desjardin Michael A. | Dosage form for administering prescribed dose |
| DE19827732A1 (de) | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
| AU4972599A (en) | 1998-07-07 | 2000-01-24 | Transdermal Technologies, Inc. | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
| US6284234B1 (en) | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
| US6096733A (en) * | 1998-12-10 | 2000-08-01 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| DE19913732A1 (de) * | 1999-03-26 | 2000-09-28 | Lohmann Therapie Syst Lts | Nikotin-TTS mit einem Zusatz von Monoterpenketonen |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6451300B1 (en) | 1999-05-03 | 2002-09-17 | The Procter & Gamble Company | Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers |
| US6962691B1 (en) | 1999-05-20 | 2005-11-08 | U & I Pharmaceuticals Ltd. | Topical spray compositions |
| DE60040293D1 (de) | 1999-07-28 | 2008-10-30 | Univ R | Verwendung von nikotin in der angiogenese und der vaskulogenese |
| FR2798065B1 (fr) * | 1999-09-02 | 2003-09-05 | Assist Publ Hopitaux De Paris | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson |
| US6562370B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
| US6562368B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
| US6586000B2 (en) * | 1999-12-16 | 2003-07-01 | Dermatrends, Inc. | Hydroxide-releasing agents as skin permeation enhancers |
| US6432446B2 (en) * | 2000-02-03 | 2002-08-13 | Bridge Pharma, Inc. | Non-arrhythmogenic metabolite of oxybutynin |
| MXPA02010542A (es) | 2000-04-26 | 2003-10-14 | Watson Pharmaceuticals Inc | Minimizacion de experiencias adversas asociadas con la terapia con oxibutinina. |
| US7029694B2 (en) * | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US20070225379A1 (en) | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| AU8206401A (en) * | 2000-08-03 | 2002-02-18 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| ES2423899T3 (es) | 2000-08-30 | 2013-09-25 | Unimed Pharmaceuticals, Llc | Método para aumentar las concentraciones de testosterona y esteroides relacionados en las mujeres |
| US6545046B2 (en) * | 2000-08-30 | 2003-04-08 | Theramax Inc. | Method for enhanced delivery of oxybutynin and compositions thereof |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| FR2814074B1 (fr) | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
| US6596740B2 (en) * | 2000-10-24 | 2003-07-22 | Richard L. Jones | Nicotine mucosal spray |
| US6479076B2 (en) * | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
| US6476012B2 (en) | 2001-01-25 | 2002-11-05 | Yale University | Estradiol-16α-carboxylic acid esters as locally active estrogens |
| EP1231158A1 (de) * | 2001-02-12 | 2002-08-14 | Hellermann Tyton GmbH | Magazinstreifen von Bandschlössern und Werkzeug für dessen Verarbeitung |
| AU2002340120A1 (en) | 2001-10-04 | 2003-04-14 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
| AU2002366800B2 (en) * | 2001-12-20 | 2006-08-03 | Femmepharma Holding Company, Inc. | Vaginal delivery of drugs |
| US6951846B2 (en) | 2002-03-07 | 2005-10-04 | The United States Of America As Represented By The Secretary Of The Army | Artemisinins with improved stability and bioavailability for therapeutic drug development and application |
| US6586449B1 (en) * | 2002-05-28 | 2003-07-01 | Cambrex Charles City, Inc. | Nicotine-containing, controlled release composition and method |
| US6889875B2 (en) | 2002-06-04 | 2005-05-10 | Cellegy Pharmaceuticals, Inc. | Taper well meter dose pump |
| DE10253216A1 (de) * | 2002-11-15 | 2004-05-27 | Cognis Deutschland Gmbh & Co. Kg | Verwendung von niedermolekularen Proteinhydrolysaten in Wasch- und Reinigungsmitteln |
| US6995265B2 (en) * | 2003-08-26 | 2006-02-07 | North Carolina State University | Synthesis of nicotine derivatives from nicotine |
| PL1670433T3 (pl) | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
| US8668925B2 (en) * | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
| FR2877143A1 (fr) * | 2004-10-25 | 2006-04-28 | St Microelectronics Sa | Cellule de memoire volatile preenregistree |
| US8067399B2 (en) | 2005-05-27 | 2011-11-29 | Antares Pharma Ipl Ag | Method and apparatus for transdermal or transmucosal application of testosterone |
| US20070048360A1 (en) * | 2005-08-23 | 2007-03-01 | R Carrara Dario N | Pharmaceutical compositions with melting point depressant agents and method of making same |
-
2004
- 2004-10-06 PL PL04790156T patent/PL1670433T3/pl unknown
- 2004-10-06 DK DK04790156.6T patent/DK1670433T3/da active
- 2004-10-06 CA CA2538856A patent/CA2538856C/en not_active Expired - Lifetime
- 2004-10-06 AT AT04790156T patent/ATE534373T1/de active
- 2004-10-06 NZ NZ546106A patent/NZ546106A/en not_active IP Right Cessation
- 2004-10-06 ES ES04790156T patent/ES2377932T3/es not_active Expired - Lifetime
- 2004-10-06 EP EP04790156A patent/EP1670433B1/en not_active Expired - Lifetime
- 2004-10-06 JP JP2006530107A patent/JP5619337B2/ja not_active Expired - Fee Related
- 2004-10-06 WO PCT/EP2004/011175 patent/WO2005039531A1/en not_active Ceased
- 2004-10-06 PT PT04790156T patent/PT1670433E/pt unknown
- 2004-10-06 BR BRPI0414551A patent/BRPI0414551B8/pt not_active IP Right Cessation
- 2004-10-06 MX MXPA06003316A patent/MXPA06003316A/es active IP Right Grant
- 2004-10-06 AU AU2004283431A patent/AU2004283431B2/en not_active Expired
-
2006
- 2006-03-07 US US11/371,042 patent/US7335379B2/en not_active Expired - Lifetime
- 2006-03-10 ZA ZA200602046A patent/ZA200602046B/en unknown
- 2006-03-24 MX MX2011005686A patent/MX343811B/es unknown
-
2008
- 2008-11-10 US US12/268,301 patent/US20090069364A1/en not_active Abandoned
-
2011
- 2011-05-12 US US13/106,530 patent/US8980309B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0414551A8 (pt) | 2017-04-11 |
| AU2004283431A1 (en) | 2005-05-06 |
| US20060153905A1 (en) | 2006-07-13 |
| US20110257141A1 (en) | 2011-10-20 |
| US20090069364A1 (en) | 2009-03-12 |
| US7335379B2 (en) | 2008-02-26 |
| NZ546106A (en) | 2008-10-31 |
| ATE534373T1 (de) | 2011-12-15 |
| EP1670433A1 (en) | 2006-06-21 |
| MXPA06003316A (es) | 2006-06-08 |
| BRPI0414551A (pt) | 2006-10-31 |
| CA2538856A1 (en) | 2005-05-06 |
| PT1670433E (pt) | 2012-02-08 |
| ZA200602046B (en) | 2007-06-27 |
| BRPI0414551B1 (pt) | 2020-08-18 |
| MX343811B (es) | 2016-11-24 |
| JP5619337B2 (ja) | 2014-11-05 |
| CA2538856C (en) | 2010-06-29 |
| US8980309B2 (en) | 2015-03-17 |
| DK1670433T3 (da) | 2012-03-12 |
| JP2007508261A (ja) | 2007-04-05 |
| AU2004283431B2 (en) | 2009-09-10 |
| BRPI0414551B8 (pt) | 2021-05-25 |
| EP1670433B1 (en) | 2011-11-23 |
| ES2377932T3 (es) | 2012-04-03 |
| WO2005039531A1 (en) | 2005-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1670433T3 (pl) | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze | |
| YU25500A (sh) | Postupak za sintezu analoga nukleozida | |
| MY142948A (en) | Benzophenones as inhibitors of reverse transcriptase | |
| IS8870A (is) | Lyfjablanda sem felur í sér andrógen | |
| MXPA05002814A (es) | Formulacion para agentes lipofilicos. | |
| JO2247B1 (en) | Method for preparing a compound | |
| GB0119011D0 (en) | Treatment of nail infections | |
| MXPA02009275A (es) | Metodo para preparar dispersiones de alta presion/alto esfuerzo cortante que contienen ingredientes fisiologicamente activos. | |
| SG148031A1 (en) | Use of cci-779 as an antineoplastic agent | |
| UA85574C2 (uk) | Ендопаразитоцидний засіб для місцевого застосування | |
| MXPA02006826A (es) | Un inhibidor de division celular y un metodo de produccion del mismo. | |
| TW200514772A (en) | Novel tetrahydropyridine derivatives | |
| NO20060631L (no) | Fast dispersjon av takrolimus | |
| HUP0401811A2 (hu) | Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására | |
| TW200501965A (en) | Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle | |
| IL160171A0 (en) | Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| DE10391147D2 (de) | Mittel zur Behandlung von Flaviviridae-Infektionen | |
| AU2001261516A1 (en) | Semi-solid delivery vehicle and pharmaceutical compositions | |
| WO2002004409A3 (en) | Tetrahydrobenzothiazole analogues as neuroprotective agents | |
| YU18601A (sh) | Postupak za dobijanje derivata resorcinola | |
| DK1427286T3 (da) | Fremgangsmåde til udtynding af frugt | |
| TW200509919A (en) | Cathepsin S inhibitors | |
| MXPA02009705A (es) | Nueva combinacion de un betabloqueador y un agente de disminucion de colesterol. | |
| UA83821C2 (ru) | Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли | |
| GR20020100478A (el) | Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης |